STERIS plc (STE) earnings on August 5, 2026
Prior outlook: Optimistic Outcome: Missed
Steris shares fell 0.60% after earnings, after a sales miss in the first quarter. The stock dropped as much as 6.42% during the day, though the full-year outlook was mostly maintained.
STE price around the earnings
231.78
Change: -0.3%
2026-08-06, 20:00 UTC
Start of the measured window
End of the measured window
220.23
224.53
228.83
233.13
232.45
August 5, 2026
August 5, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Missed
- Thesis published
- Results released
Strong positive trend strength, analyst bullishness, and recent positive news, but mixed past earnings.
Context analyzed before publication
- Trend
- Strong positive trend strength and analyst bullishness, with a significant run-up into earnings.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.78
- Analysts covering the stock
- 8
- Average price target
- 255.38
- Lowest price target
- 225
- Highest price target
- 280
- Upside to price target
- 10.6%
- Quarterly earnings growth
- 51.2%
- Revenue growth
- 7.3%
- Forward EPS
- 12.21
- Trailing EPS
- 7.94
- Analyst moves in the last 60 days
- 1
- Strong buy: 3
- Buy: 4
- Hold: 2
- Sell: 0
- Strong sell: 0
- Strong buy
- 3
- Buy
- 4
- Hold
- 2
- Sell
- 0
- Strong sell
- 0
- July 28, 2026 · UBS: Initiates coverage (Buy)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (3)
- STERIS Plans $600M Investment To Construct Formulated Chemistries Manufacturing And Distribution Center Of Excellence In North Carolina (opens in a new tab) — Benzinga
- STERIS Raises Quarterly Dividend From $0.63 To $0.69 Per Share (opens in a new tab) — Benzinga
- UBS Initiates Coverage On Steris with Buy Rating, Announces Price Target of $275 (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 233.36
- Average true range (ATR)
- 2.3%
- Distance to 52-week high
- -13.6%
- 14-day change (14d)
- +10.2%
- 30-day change (33d)
- +7.0%
- 30-day relative strength
- +3.4%
- SPY change (33d)
- +3.5%
- Nearest support
- 232.37
- Distance to nearest support
- 0.4%
- Nearest resistance
- 234.49
- Distance to nearest resistance
- 0.5%
- Volume accumulation ratio (14d / 46d)
- 0.82
- Mid: 232.37 (0.4% away, 0.18 ATR, 17 touches)
- Mid: 230.73 (1.1% away, 0.48 ATR, 15 touches)
- Mid: 229.72 (1.6% away, 0.67 ATR, 15 touches)
- Major: 234.49 (0.5% away, 0.21 ATR, 26 touches)
- Major: 235.46 (0.9% away, 0.39 ATR, 24 touches)
- Major: 236.61 (1.4% away, 0.6 ATR, 26 touches)
Trends
Evidence
- Average earnings surprise
- +1.9%
- May 11, 2026: actual EPS 2.83 vs estimate 2.85 (surprise -0.7%)
- February 4, 2026: actual EPS 2.53 vs estimate 2.53 (surprise -0.1%)
- November 5, 2025: actual EPS 2.47 vs estimate 2.35 (surprise +5.0%)
- August 6, 2025: actual EPS 2.34 vs estimate 2.26 (surprise +3.4%)
Expected move
- Implied move
- +2.1%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 5.5%
- 75th percentile move
- 7.7%
- 90th percentile move
- 9.8%
- Up / down moves
- 11 / 9
- Average up move
- +5.4%
- Average down move
- -5.7%
Monitoring and close
What STERIS plc reported
- Status
- Finished
| Actual EPS | 2.59 |
|---|---|
| EPS estimate | 2.5 |
| EPS surprise | +3.6% |
Steris reported first-quarter sales of $1.493 billion, missing estimates, but beat adjusted earnings expectations. It affirmed annual guidance.
Sources (5)
- Steris Q1 Sales $1.493B Miss $1.498B Estimate (opens in a new tab) — Benzinga
- Steris Affirms FY2027 GAAP EPS Guidance of $9.00-$9.20 vs $9.08 Est (opens in a new tab) — Benzinga
- Steris Widens FY2027 Adj EPS Guidance from $11.10-$11.30 to $11.00-$11.30 vs $11.16 Est; Affirms FY2027 Sales Guidance of $6.352B-$6.411B vs $6.371B Est (opens in a new tab) — Benzinga
- Steris beat expectations with adjusted earnings of $2.59 per share, versus the $2.50 estimate. — Benzinga
- Steris Q1 Adj. EPS $2.59 Beats $2.50 Estimate (opens in a new tab) — Benzinga
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations and the price is indicating -2.2% pre-market, a move below the stock's usual reaction (about 5%). The figures don't confirm the prior scenario: the price move doesn't follow the direction the results point to.
How the stock reacted
- Outcome
- Missed
- Consolidated
- -0.6%
- Max favorable move (MFE)
- 0.4%
- Max adverse move (MAE)
- 6.4%